Patient must have fully recovered from the effects of prior surgery at least 14 days prior to sub-study registration
Patients may have received prior surgery; at least 28 days must have elapsed since surgery and patient must have recovered from any adverse effects of surgery
Surgery (partial or gross total resection or biopsy) must be performed >= 2 weeks prior to registration; patient must have recovered adequately from the effects of surgery
The patient must have recovered from effects of surgery, postoperative infection, and other complications within 28 days prior to step 2 registration
Patient must have recovered from the surgery
Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy
Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy to CTCAE v4.03 grade 1, baseline or less, except for alopecia
Major surgery =< 2 weeks prior to registration or who have not recovered from side effects of such therapy; subjects must have recovered from any effects of recent radiotherapy that might confound the safety evaluation of study drug
Patients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy; they should be free of significant infection
The patient must have recovered from the effects of surgery, postoperative infection and other complications before enrollment;
Patients must be at least 4 weeks from radiation or surgery and recovered from all ill effects
Patients with a recent surgery should have recovered from all effects of the surgery and be cleared by their surgeon
Must have recovered from effects of surgery, postoperative infection and other complications of surgery
Patients must have recovered from the effects of prior therapy
Patients must have recovered from effects of recent surgery, radiotherapy, or chemotherapy
Must have recovered from adverse effects of any prior surgery, radiotherapy or other antineoplastic therapy
Any patient who has had a recent surgery should have recovered from all effects of the surgery and be cleared by their surgeon
Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
Patients must be deemed by the investigators to be fully recovered from both acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy
Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
PHASE I: Recovery from effects of recent surgery, radiotherapy, or chemotherapy must be demonstrated
PHASE II: Recovery from effects of recent surgery, radiotherapy, or chemotherapy must be demonstrated
Not recovered to Grade 1 from adverse effects of prior myeloma therapy or radiotherapy prior to screening.
Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected; the subject should have recovered from the effects of these or of any prior surgery
Recovered from effects of any prior surgery or cancer therapy
Patients must not have chemotherapy, radiotherapy, chemoembolization, radioembolization, or immunoembolization for their malignancy within 30 days prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventions except those listed in Appendix B of the study protocol.
Patients must have recovered from the surgery
Have recovered from the effects of any prior radiotherapy or surgery;
Recovery from the effects of prior therapy:
At least 4 weeks and recovery from effects of prior surgery, prior radiotherapy, or other therapy with an approved or investigational agent
Participant must have recovered from the effects of surgery, postoperative infection, and other complications; has no significant post-operative hemorrhage.
Subjects must have recovered from surgery before study registration
Recovery from effects of recent surgery, radiotherapy, or chemotherapy
Patients must be recovered from both the acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy
Patients must be recovered from both the acute and late effects of any prior surgery, radiotherapy, or other antineoplastic therapy
Patients must have recovered from effects of recent surgery, radiotherapy or chemotherapy
Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.
Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior system anticancer therapy, radiotherapy or surgery.
Patients must be recovered from effects of recent surgery (28 days must elapse between surgery and the start of treatment with cabozantinib)
Patients with recent resection for recurrent disease must have recovered from the effects of surgery and should not start treatment for at least 28 days after surgery
Patients may have received prior surgery; however, at least 21 days must have elapsed since completion of surgery and the patient must have recovered from all side effects
The patient must have recovered from the effects of surgery, post-operative infection, and other complications before study registration.
Patients who have not recovered from prior surgery
Recovered from effects of recent surgery, radiotherapy, or chemotherapy
Patients must have had no chemotherapy, radiotherapy, or biologic therapy for their malignancy in the month prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventions
Participants must have recovered from the acute effects of chemotherapy and radiotherapy and from surgical side effects following definitive breast surgery.
The patient is, in the investigator's opinion, adequately recovered from the effects of surgery and chemoradiotherapy to participate in this study.
Subjects who have not recovered from the effects of recent surgery
Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy, up to CTCAE grade 1
Patients must be recovered from acute and late effects of any prior surgery, radiotherapy or other anti-neoplastic therapy
Subjects must be recovered from the effects of any prior chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy or surgery
Recovery from effects of recent surgery, radiotherapy, or chemotherapy
Patients must have recovered from the effects of prior surgery.
Recovered from the effects of any prior systemic therapy, radiotherapy or surgery
Must have recovered from all side effects of their most recent systemic or local treatment
Patients who have not recovered from symptomatic side effects of radiotherapy at the time of initiation of screening procedure.
Recovery from the effects of surgery.
Recovered from effects of recent surgery, radiotherapy, and chemotherapy
Patients must be recovered from the effects of any prior surgery, radiotherapy, or other antineoplastic therapy
Recovered from the effects of prior antineoplastic therapy
Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy. Up to CTCAE Grade 1 is acceptable for patients with known peripheral neuropathy
Previous chemotherapy, and/or biological therapy for cancer are permitted provided that the acoustic properties of the tumor were not affected, but the subject should have recovered from the effects of these or of any prior surgery
Patients having undergone recent resection (within 5 weeks prior to registration) of their glioblastoma to treat current recurrence prior to study treatment must have recovered from the effects of surgery (including patient's skin having fully recovered from the surgical wound) Note: a 4-week window is required after surgery prior to starting treatment. For CNS-related stereotactic biopsies, a minimum of 7 days must have elapsed prior to registration.
Patients must have recovered from prior surgery
Patients must have completed mastectomy or breast-sparing surgery and must have recovered from all side effects of the surgery; if patients were treated with chemotherapy and/or radiation therapy, these treatments must be completed at least 28 days prior to study registration; patients should have recovered from all grade 2 or higher side effects of chemotherapy and/or radiation therapy with the exception of alopecia and peripheral neuropathy; concurrent bisphosphonate and trastuzumab therapies are allowed
Recovered from the effects of any prior surgery or radiotherapy
recovered from any prior surgery
